FDA Drug Approvals: Oncology and Hematology — Year in Review 2018

• New Drugs for Non-Small Cell Lung Cancer
  Vizimpro (dacomitinib), Lorbrena (lorlatinib)

• New Drugs for Metastatic Melanoma
  Braftovi (encorafenib), Mektovi (binimetinib)

• New Drugs for Leukemia or Lymphoma
  Copiktra (duvelisib), Lumoxiti (moxetumomab pasudotox), Poteligeo (mogamulizumab), Asparlas (calaspargase pegol), Elzonris (tagraxofusp)

• New Drugs for Acute Myeloid Leukemia
  Xospata (gilteritinib), Daurismo (glasdegib), Tibsovo (ivosidenib)

• Other New Oncology Drugs
  Vitrakvi (larotrectinib), Libtayo (cemiplimab), Talzenna (talazoparib), Erleada (apalutamide), Lutathera (lutetium Lu 177-dota-tate), Akynzeo (netupitant/palonosetron)

• New Drugs for Hematology
  Doptelet (avatrombopag), Mulpleta (lusutrombopag), Tavalisse (fostamatinib), Ultomiris (ravulizumab)

Medscape © 2019 WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Mary L Windle. FDA Drug Approvals: Oncology and Hematology — Year in Review 2018 - Medscape - Jan 15, 2019.